
Manolis Kellis: Biology of Disease | Lex Fridman Podcast #133
Lex Fridman (host), Manolis Kellis (guest), Narrator, Narrator, Lex Fridman (host), Narrator, Narrator
In this episode of Lex Fridman Podcast, featuring Lex Fridman and Manolis Kellis, Manolis Kellis: Biology of Disease | Lex Fridman Podcast #133 explores decoding Human Disease: Genetics, Brain Circuits, and Future Therapies Lex Fridman and Manolis Kellis explore how modern human genetics and computational biology are transforming our understanding of complex diseases such as obesity, Alzheimer’s, schizophrenia, heart disease, and metabolic disorders.
Decoding Human Disease: Genetics, Brain Circuits, and Future Therapies
Lex Fridman and Manolis Kellis explore how modern human genetics and computational biology are transforming our understanding of complex diseases such as obesity, Alzheimer’s, schizophrenia, heart disease, and metabolic disorders.
Kellis explains the shift from traditional one-gene, animal-model biology to large-scale human genomics, where millions of natural genetic perturbations across thousands of people and phenotypes reveal causal mechanisms of disease.
They dive into multi-layered biological circuitry—from DNA variants, epigenomics, and gene expression to cell types, organs, and behavior—and show how convergent pathways (like calcium signaling, immune function, and energy metabolism) emerge across many diseases.
The discussion highlights powerful new tools (CRISPR, single-cell sequencing, high-throughput assays, AI-driven analysis) that enable systematic mapping of disease circuitry and point toward a coming era of precision, systems-level, and multi-target therapeutics.
Key Takeaways
Human genetics has flipped the old model of biology on its head.
Instead of learning basic mechanisms in mice and then mapping them to humans, we now use the vast diversity of human genetic variants and natural 'experiments' to discover causal genes, pathways, and tissues, which then drive basic biological insight.
Get the full analysis with uListen AI
Most disease variants act through gene regulation, not by breaking proteins.
About 93% of disease-associated variants lie outside protein-coding regions, mainly in regulatory elements (enhancers), so understanding long-range genome circuitry—what variants control which genes in which cell types—is essential for pinpointing mechanisms and drug targets.
Get the full analysis with uListen AI
Complex diseases are polygenic but converge on a limited set of pathways.
Thousands of small-effect variants and regulatory elements may differ between people, but they often funnel into common processes (e. ...
Get the full analysis with uListen AI
Multi-level data integration is key to decoding disease mechanisms.
By linking genetic variants to epigenomic marks, gene expression, single-cell profiles, cell-to-cell communication, organ-level measures, and clinical phenotypes, researchers can trace full causal chains from a nucleotide change to molecular, cellular, and behavioral outcomes.
Get the full analysis with uListen AI
New experimental platforms let scientists test thousands of hypotheses in parallel.
Technologies such as massively parallel reporter assays (MPRA), high-throughput CRISPR perturbations, and single-cell RNA/ATAC sequencing enable simultaneous testing of tens of thousands of variants, enhancers, and genes, dramatically accelerating the mapping of disease circuitry.
Get the full analysis with uListen AI
The FTO obesity locus illustrates how deep circuitry analysis enables interventions.
What was thought to be an obesity gene (FTO) turned out to be a regulatory region controlling distant genes IRX3/IRX5 in fat progenitors, tipping cells between energy-burning (thermogenic) and energy-storing fat; a single base change can flip cellular behavior, revealing multiple potential therapeutic levers.
Get the full analysis with uListen AI
The future of medicine is systems-level, personalized, and multi-target.
Kellis envisions treatments that consider an individual’s common, rare, and somatic variants, their molecular and clinical profiles, and then use combinatorial interventions (DNA/RNA drugs, cell-type-specific constructs, small molecules) to modulate whole networks rather than single genes, while minimizing on-target side effects.
Get the full analysis with uListen AI
Notable Quotes
“Understanding human disease is the most complex challenge in modern science.”
— Manolis Kellis
“You cannot solve disease with traditional biology. You have to think genomically.”
— Manolis Kellis
“This is a paper about one nucleotide in the human genome… one bit of information.”
— Manolis Kellis
“The confluence of technologies, computation, data, insight, and tools for manipulation is unprecedented in human history.”
— Manolis Kellis
“Disease is gonna be fundamentally altered and alleviated as we go forward.”
— Manolis Kellis
Questions Answered in This Episode
How should we ethically handle personal genetic risk information, given that it can shape life choices but also cause anxiety or discrimination?
Lex Fridman and Manolis Kellis explore how modern human genetics and computational biology are transforming our understanding of complex diseases such as obesity, Alzheimer’s, schizophrenia, heart disease, and metabolic disorders.
Get the full analysis with uListen AI
If most disease variants act through regulation rather than coding changes, how might that change drug discovery and target prioritization strategies in pharma?
Kellis explains the shift from traditional one-gene, animal-model biology to large-scale human genomics, where millions of natural genetic perturbations across thousands of people and phenotypes reveal causal mechanisms of disease.
Get the full analysis with uListen AI
What are the biggest computational bottlenecks in integrating multi-omic and single-cell data into actionable clinical insights?
They dive into multi-layered biological circuitry—from DNA variants, epigenomics, and gene expression to cell types, organs, and behavior—and show how convergent pathways (like calcium signaling, immune function, and energy metabolism) emerge across many diseases.
Get the full analysis with uListen AI
How could systems-level, multi-gene interventions be tested safely in humans, given the potential for complex and unforeseen network effects?
The discussion highlights powerful new tools (CRISPR, single-cell sequencing, high-throughput assays, AI-driven analysis) that enable systematic mapping of disease circuitry and point toward a coming era of precision, systems-level, and multi-target therapeutics.
Get the full analysis with uListen AI
To what extent might future therapies blur the line between treating disease and enhancing normal human traits like cognition, stamina, or metabolism?
Get the full analysis with uListen AI
Transcript Preview
The following is a conversation with Manolis Kellis, his third time on the podcast. He's a professor at MIT, and head of the MIT Computational Biology Group. This time, we went deep on the science, biology, and genetics. So this is a bit of an experiment. Manolis went back and forth between the basics of biology to the latest state-of-the-art in the research. He's a master at this. So I just sat back and enjoyed the ride. This conversation happened at 7:00 AM (laughs) , so it's yet another podcast episode after an all-nighter for me. And once again, since the universe has a sense of humor, this one was a tough one for my brain (laughs) to keep up, but I did my best, and I never shy away from a good challenge. Quick mention of each sponsor, followed by some thoughts related to the episode. First is SEMrush, the most advanced SEO optimization tool I've ever come across. I don't like looking at numbers, but someone probably should. It helps you make good decisions. Second is Pessimist Archive. They're back. One of my favorite history podcasts on why people resist new things, from recorded music to umbrellas, to cars, chess, coffee, and the elevator. Third is Eight Sleep, a mattress that cools itself, measures heart rate variability, has an app, and has given me yet another reason to look forward to sleep, including the all-important power nap. And finally, BetterHelp, online therapy when you want to face your demons with a licensed professional, not just by doing the, uh, David Goggins-like physical challenges like I seem to do on occasion. Please check out these sponsors in the description to get a discount and to support this podcast. As a side note, let me say that biology in the brain and in the various systems of the body fill me with awe. Every time I think about how such a chaotic mess coming from its humble origins in the ocean was able to achieve such incredibly complex and robust mechanisms of life that survived despite all the forces of nature that want to destroy it. It is so unlike the computing systems we humans have engineered that it makes me feel that in order to create artificial general intelligence and artificial consciousness, we may have to completely rethink how we engineer computational systems. If you enjoy this thing, subscribe on YouTube, review it with five stars on Apple Podcasts, follow on Spotify, support on Patreon, or connect with me on Twitter @lexfridman. And now, here's my conversation with Manolis Kellis. So your group at MIT is trying to understand the molecular basis of human disease. What are some of the biggest challenges in your view?
Don't get me started.
(laughs)
I mean-
Here we go again.
... understanding human disease is the most complex, uh, challenge in modern science. So because human disease is as complex as the human genome, it is as complex as the human brain, and it is in many ways even more complex, because the more we understand disease complexity, the more we start understanding genome complexity, and epigenome complexity, and brain circuitry complexity, and immune system complexity, and cancer complexity, and so on and so forth. So traditionally, human disease was following basic biology. You would basically understand basic biology in model organisms, like, you know, mouse and fly and yeast. You would understand sort of mammalian biology and animal biology and eukaryotic biology in sort of progressive layers of complexity, getting closer to human, phylogenetically. And you would do perturbation experiments in those species to see, "If I knock out a gene, what happens?" And based on the knocking out of these genes, you would basically then have a way to drive human biology, because you would, you would sort of understand the functions of these genes. And then if you find that a human gene locus, something that you've mapped from human genetics to that gene, is related to a particular human disease, you'd say, "Aha, now I know the function of the gene from the model organisms. I can now go and understand the function of that gene in human." But this is all changing. This is dramatically changed. So that, that was the old way of doing basic biology. You would start with the animal models, the eukaryotic models, the mammalian models, and then you would go to human. Human genetics has been so transformed in the last decade or two that human genetics is now actually driving the basic biology. There is more genetic mutation information in the human gene- genome than there will ever be in any other species.
Install uListen to search the full transcript and get AI-powered insights
Get Full TranscriptGet more from every podcast
AI summaries, searchable transcripts, and fact-checking. Free forever.
Add to Chrome